**Supplementary Table 1: Patients treated with pembrolizumab according to clinical site**

|  |  |
| --- | --- |
| **Clinical site** | **Pembrolizumab** |
| **Cohort 1 (n=177)** | **Cohort 2 (n=182)** | **Cohort 3 (n=257)** | **Total (n=616)** |
| n | % | n | % | n | % | n | % |
| Amsterdam |  |  | 47 | 25.8 | 10 | 3.9 | 57 | 9.3 |
| Berlin |  |  | 2 | 1.1 | 2 | 0.8 | 4 | 0.6 |
| Bonn |  |  | 2 | 1.1 | 1 | 0.4 | 3 | 0.5 |
| Dresden | 6 | 3.4 |  |  |  |  | 6 | 1.0 |
| Erlangen | 11 | 6.2 |  |  | 4 | 1.6 | 15 | 2.4 |
| Essen |  |  | 28 | 15.4 | 4 | 1.6 | 32 | 5.2 |
| Freiburg | 4 | 2.3 |  |  |  |  | 4 | 0.6 |
| Groningen |  |  | 20 | 11.0 | 6 | 2.3 | 26 | 4.2 |
| Hannover | 10 | 5.6 |  |  | 4 | 1.6 | 14 | 2.3 |
| Heidelberg | 31 | 17.5 |  |  | 11 | 4.3 | 42 | 6.8 |
| Homburg |  |  |  |  | 2 | 0.8 | 2 | 0.3 |
| Jena |  |  | 2 | 1.1 | 2 | 0.8 | 4 | 0.6 |
| Kiel | 9 | 5.1 |  |  | 9 | 3.5 | 18 | 2.9 |
| Köln | 11 | 6.2 |  |  | 6 | 2.3 | 17 | 2.8 |
| Lausanne |  |  | 9 | 4.9 |  |  | 9 | 1.5 |
| Leipzig |  |  | 3 | 1.6 |  |  | 3 | 0.5 |
| Lübeck |  |  | 2 | 1.1 |  |  | 2 | 0.3 |
| Ludwigshafen |  |  | 3 | 1.6 |  |  | 3 | 0.5 |
| Mannheim | 9 | 5.1 |  |  | 1 | 0.4 | 10 | 1.6 |
| Marburg |  |  | 8 | 4.4 | 4 | 1.6 | 12 | 1.9 |
| München | 19 | 10.7 |  |  | 4 | 1.6 | 23 | 3.7 |
| Münster |  |  | 3 | 1.6 |  |  | 3 | 0.5 |
| Nantes |  |  | 2 | 1.1 |  |  | 2 | 0.3 |
| Napoli |  |  | 28 | 15.4 | 20 | 7.8 | 48 | 7.8 |
| New York |  |  |  |  | 141 | 54.9 | 141 | 22.9 |
| Nürnberg |  |  | 1 | 0.5 | 2 | 0.8 | 3 | 0.5 |
| Regensburg | 1 | 0.6 |  |  |  |  | 1 | 0.2 |
| Siena |  |  | 18 | 9.9 | 2 | 0.8 | 20 | 3.2 |
| Tübingen | 37 | 20.9 | 4 | 2.2 | 12 | 4.7 | 53 | 8.6 |
| Zürich | 29 | 16.4 |  |  | 10 | 3.9 | 39 | 6.3 |